Volume 4, Issue 4
Editorialp. 289–291
Cancer stem cells as a therapeutic target of the future
Author(s): Jiri Hatina
Editorialp. 293–295
Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy
Author(s): Soraru Gianni
Editorialp. 297–299
Novel therapeutics for cystic fibrosis: what does the future hold?
Author(s): Carlos E Milla
News and Viewsp. 301–304
Clinical trial success influenced by biomarker- and receptor-targeted therapies
Review: Clinical Trail Outcomesp. 305–311
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Author(s): Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomesp. 313–326
Slowing progression of idiopathic pulmonary fibrosis with pirfenidone: from clinical trials to real-life experience
Author(s): Vincent Cottin, M Wijsenbeek, F Bonella & C Vancheri
Review: Clinical Trail Outcomesp. 327–341
Treatment of albuminuria due to diabetic nephropathy: recent trial results
Author(s): Edward J Horwitz & Jeffrey R Schelling
Review: Clinical Trail Outcomesp. 359–343
Emerging approaches to the treatment of ventilator-associated pneumonia
Author(s): B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomesp. 361–371
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection
Author(s): Christoph Honer zu Siederdisse & Markus Cornberg
Research Articlep. 373–380
Geographic distribution of clinical trials may lead to inequities in access
Author(s): Elizabeth M Seidler, Aparna Keshaviah, Case Brown, Elizabeth Wood, Lisa Granick & Alexandra B Kimball
Erratump. 382
